Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570011 · ClinicalTrials.gov registry record · Phase 3
Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT00570011 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 112 participants.
The verdict
NCT00570011, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
An international study in which patients with GHD were randomized to receive somatropin at a dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months. The dose was then doubled (6 microg/kg/day, LD or 12 microg/kg/day, CD) for the next three-months.
Interventions
- DRUG Somatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 1997-06 |
| Est. Completion | 1998-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570011
The ClinicalTrials.gov registry entry for NCT00570011 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Somatropin is the first listed.
NCT00570011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570011 about?
NCT00570011 is a clinical study titled "Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients". An international study in which patients with GHD were randomized to receive somatropin at a dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months. The dose was then doubled (6 microg/kg/day, LD or 12 microg/kg/day, CD) for the next three-months.
What is the current status of trial NCT00570011?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 1997-06. Estimated completion is 1998-12.
What interventions are being tested in trial NCT00570011?
The interventions under investigation include: Somatropin (DRUG).
Who is sponsoring clinical trial NCT00570011?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.